Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04576793 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Longitudinal Imaging of Microglial Activation in Different Clinical Variants of Alzheimer's Disease

Study acronym: ADVISe
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Lead sponsor: Patrick Lao to Columbia University Primary and study completion dates: May 31, 2026 to May 31, 2027v7 Show 1 more changeShow less
    • Primary and study completion dates: May 31, 2026 to May 31, 2027
  2. Re-verified, no change to tracked fieldsv6
  3. Lead sponsor: James M Noble, MD, MS, CPH, FAAN to Patrick Lao Primary and study completion dates: May 31, 2025 to May 31, 2026 · Eligibility criteria shortened, about 20 words · Site contact updatedv5 Show 3 more changesShow less
    • Primary and study completion dates: May 31, 2025 to May 31, 2026
    • Eligibility criteria shortened, about 20 words
    • Site contact updated

    See this version in full on ClinicalTrials.gov ↗

  4. Lead sponsor: William Charles Kreisl to James M Noble, MD, MS, CPH, FAAN Site contact updated · Eligibility criteria shortened, about 1 wordv4 Show 2 more changesShow less
    • Site contact updated
    • Eligibility criteria shortened, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  5. Interventions: 11C-ER176 (Drug), 18F-Florbetaben (Drug), 18F-MK-6240 (Drug), Lumbar Puncture (Procedure) to 11C-ER176 (Drug), 18F-Florbetaben (Drug), 18F-MK6240 (Drug), Lumbar Puncture (Procedure) Study description expanded, about 25 wordsv3 Show 1 more changeShow less
    • Study description expanded, about 25 words

    See this version in full on ClinicalTrials.gov ↗

  6. Start date changed from estimate of Nov 1, 2020 to Nov 17, 2020 Eligibility criteria revisedv2 Show 1 more changeShow less
    • Eligibility criteria revised

    See this version in full on ClinicalTrials.gov ↗

  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to determine how inflammation is related to other changes in the brain that occur during the progression of Alzheimer's disease. The investigators are also studying how inflammation is related to the symptoms that first occur in patients with Alzheimer's disease (AD). For this reason, the investigators are asking people with different versions of Alzheimer's disease and/or other related dementias to participate. This includes patients with: * Mild Cognitive Impairment * Posterior cortical atrophy - a version of Alzheimer's disease with vision difficulties * Logopenic variant primary progressive aphasia - a version of Alzheimer's disease with language difficulties * Amnestic Alzheimer's disease - a "typical" version of Alzheimer's disease with memory difficulties * The investigators are also enrolling older adults with normal visual, language, and memory function.
Trial Details
NCT Number NCT04576793
Lead Sponsor Columbia University
Collaborators: National Institute on Aging (NIA)
Conditions Alzheimer Disease
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov